Pieris Proteolab AG
Executive Summary
Pieris ProteoLab was founded in February 2001 to commercialize anticalins, a novel class of antibody mimetics based on a lipocalin scaffold. Due to their molecular architecture, anticalins offer some distinct advantages over antibodies; Pieris will exploit these advantages in developing new drugs for oncology and inflammatory diseases.
You may also be interested in...
Senexis Ltd.
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.
Working Around Pre-Emption Rights
Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.
Private Device Companies Step-Up to the Public Market
Encouraged by successes in the biotech space, public market investors' interest in the device arena has returned in 2004 to support 10 companies' IPOs so far. Windhover's analysis of the valuations achieved indicate that private investors in these companies have, on average, enjoyed larger returns than their biotech counterparts.